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Mutations in the hTERT promoter responsible for constitutive telomerase activity are the most frequent
genetic alteration detected in anaplastic thyroid cancer (ATC), and proposed as diagnostic and prognostic
biomarker in these tumours. In this study we analyzed hTERT expression in a series of human ATCs and
investigated the effects of small-interfering RNA-mediated silencing of hTERT on viability and migration
and invasive properties of three human ATC cell lines. Expression of hTERTmRNA resulted increased in 8/
10 ATCs compared to normal thyroid tissues. Silencing of hTERT in CAL-62, 8505C and SW1736 cells did
not modify telomere length but determined a significant decrease (about 50%) of cell proliferation in all
cell lines and a great reduction (about 50%) of migration and invasion capacity. These finding demon-
strate that hTERT may be considered as a molecular target for ATC treatment.
© 2017 Elsevier B.V. All rights reserved.1. Introduction
Telomerase reverse transcriptase (TERT) is a catalytic subunit of
telomerase, a ribonucleoprotein polymerase acting in maintenance
of telomere length at the end of chromosomes, which plays a key
role in cellular immortality and tumorigenesis. In normal somatic
cells, repressed activity of telomerase is associated with a pro-
gressive shortening of telomeres, which leads to growth arrest. In
contrast, it is constitutively active in several cancer cells in which
permits telomeres maintenance and unlimited cellular prolifera-
tion (Skvortzov et al., 2009; Liu and Xing, 2016). Interestingly, a; ATC, anaplastic thyroid car-
FPE, formalin-fixed paraffin-
dle aspiration biopsy; TERT,
Sciences, University “Magna
opa, 88100 Catanzaro, Italy.correlation between hTERT mRNA expression and telomerase ac-
tivity has been described in cancer cells of various origin (Toshikuni
et al., 2000; Kirkpatrick et al., 2003; Zhang et al., 2006a).
In tumour cells, telomerase activation may be due to hTERT gene
amplification, engagement of TERT alternative splicing or somatic
mutations in the hTERT promoter (Skvortzov et al., 2009). The latter
ones have been described as the most frequent genetic alterations
of anaplastic thyroid cancer (ATC), the most aggressive histotype of
thyroid neoplasms (Liu et al., 2013). In these tumours, as in the
majority of human neoplasia, the frequent cytosine-to-thymine
transition in the hTERT promoter determines an activation of
hTERT transcriptional activity in cancer cells (Horn et al., 2013; Liu
et al., 2013; Killela et al., 2013). An overexpression of hTERT has
recently been described in a series of thyroid tumours, which
included also some lymph node metastatic tissues, but not ATCs
(Muzza et al., 2015).
Silencing hTERT to inhibit the telomerase activity and cell pro-
liferation of cancer cells has successfully been adopted in some
experimental models of cancer, as hepatocellular, breast and
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et al., 2006a, 2006b; de Souza Nascimento et al., 2006; Dong et al.,
2009). In this study, we analyzed hTERT mRNA expression in a se-
ries of human ATC and investigated the effects of small-interfering
RNA-mediated silencing of hTERT on the viability, migration, and
invasive properties of three human anaplastic thyroid cancer cell
lines harboring (8505C and SW1736 cells) or not (CAL-62 cells) a
mutation in hTERT promoter.2. Materials and methods
2.1. Collection of thyroid tissues
Ten patients with ATC have been enrolled at the “Sapienza”
University Hospital of Rome (Italy) (n ¼ 5) and at University Hos-
pital of Perugia (Italy) (n ¼ 5). Fresh-frozen thyroid tumour tissues
(FF) and formalin-fixed paraffin-embedded (FFPE) thyroid tumour
sections have been collected in each centre, respectively. Eighteen
thyroid adjacent non-tumour tissues (i.e. nine FF thyroid biopsy
specimens and nine FFPE thyroid samples) from patients subjected
to total thyroidectomy for sporadic thyroid cancer at the “Sapienza”
University Hospital of Rome were collected. Samples were selected
for a tumour sample cellularity more than 60% and for absence of
signs of inflammation or other types of disease in the normal thy-
roid tissues. Clinical data were collected by retrospective review of
hospital charts and tumours were classified according to the
American Joint Committee on Cancer TNM staging system (Table 1).
The study was approved by the local medical ethics committee.2.2. Extraction of RNA and gene expression studies
TRIzol reagent was used for RNA isolation from FF tissues and
thyroid cell lines (Thermo Fisher Scientific Inc., Waltham, MA, USA)
(Sponziello et al., 2016). Recover All Total Nucleic Acid Isolation Kit
(Thermo Fisher Scientific Inc.) was used for RNA isolation from FFPE
thyroid tissue specimens. cDNA synthesis was performedwith High
Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific
Inc.) from 1 mg of total RNA. mRNA levels of hTERTwere assessed in
thyroid tissues and cell lines by real time PCR on a 7900 HT Fast
Real-time PCR System (Thermo Fisher Scientific Inc.) following
standard procedures. Data analyses were carried out using SDS 2.4
software (Thermo Fisher Scientific Inc.). Final results were deter-
mined by the comparative 2DDCt method using beta-2 micro-
globulin (tissues) or beta-actin (cell lines) as endogenous control,
and shown as relative expression normalized to a calibrator sample
group (adjacent non-tumour thyroid tissues from FF or FFPE sam-
ples and Nthy-ori-3-1 cells).Table 1
Clinical Characteristics of ATC patients.
# Sex Age at diagnosis T N M* STAGE BRAF TERT
1 M 61 4b 1b 0 IVb WT C228T
2 M 69 4b 1 x IVb WT C228T
3 F 65 4b 1b x IVb WT WT
4 M 31 4b 1 0 IVb WT WT
5 F 35 4b 0 1 IVc WT WT
6 M 87 4b 1b x IVb WT WT
7 F 72 4b 0 1 IVc WT C228T
8 M 31 4b 0 0 IVb WT WT
9 M 74 NA NA NA NA WT C228T
10 M 78 4b 1b* x IVb V600E C228T
Abbreviations F, female; M, male; M*, metastase; N, node; NA, not available; T,
tumour; WT, wild type.2.3. Thyroid cell lines and hTERT silencing
In this study, we used three human anaplastic thyroid carci-
noma cell lines: 8505C and SW1736, characterized by the presence
of BRAFV600E mutation as well as C250T and C253T (for 8505C) or
C228T (for SW1736) mutations of hTERT promoter, and CAL-62,
which does not bear either BRAFV600E or hTERT promoter muta-
tion (Schweppe et al., 2008; Liu et al., 2013; Jeon et al., 2016). As
control, we used the non-tumorigenic Nthy-ori-3-1 cells
(Sponziello et al., 2016). Short Tandem Repeat analysis was per-
formed to check the genomic stability of these cell lines. Cells were
cultured in RPMI or DMEM (Thermo Fisher Scientific Inc.) medium
at 37 C in a humidified 5% CO2 as previously described (Celano
et al., 2015; Sponziello et al., 2016). Three different hTERT-specific
siRNA (sihTERT) (sequences 50 to 30: a. AGGCACUGUU-
CAGCGUGCUCAACUA; b. GCCUGUUUCUGGAUUUGCAGGUGAA c.
CCUCUGUGCUGGGCCUGGACGAUAU were transiently transfected
into cells using lipofectamine RNAiMAX (Thermo Fisher Scientific
Inc.), following the manufacturer's instructions. Briefly, cells were
plated in 6 well plates (130  103/well) and the next day, when the
cells had reached 60e80% confluence, the medium was replaced
with freshmediumwith siRNA hTERT a, b, or c. After further 4 h, the
medium was replaced again with fresh medium. After 48 h,
transfection efficiency was evaluated by RT-PCR and western blot
assays. In all experiments, control is indicated as siCtrl and repre-
sents cells transfected with Stealth RNAi Negative Control Duplexes
(Thermo Fisher Scientific Inc.).
2.4. DNA extraction and telomere length assay
After hTERT silencing, genomic DNA of 8505C, CAL-62 and
SW1736 cells was isolated by the Gentra Puregene Cell Kit (Qiagen,
Hilden, Germany), according to the manufacturer protocol. The
mean telomere length was evaluated by using the TeloTAGGG
Telomere Length Assay kit (Hoffmann-La Roche Ltd, Basel,
Switzerland). Briefly, 2 mg of genomic DNA were digested with re-
striction enzymes HinfI and RasI for 2 h at 37 C and then separated
on 0.8% (w/v) agarose gel. The DNA fragments were capillary
transferred to a positively charged nitrocellulose membrane (GE
Healthcare, Little Chalfont, United Kingdom) in 20x saline-sodium
citrate buffer overnight at room temperature. After UV-
crosslinking, the membrane was hybridized with a DIG-labeled
probe specific for telomeric repeats and incubated with a DIG-
antibody coupled to alkaline phosphatase. The signal was detec-
ted using a highly sensitive chemiluminescent substrate CDP-star.
Telomere length was calculated using the UVITEC Alliance LD
(UVITec Limited, Cambridge, United Kingdom) with the Super-
Signal Technology (Thermo Fisher Scientific Inc.). The calculation of
mean TRF length was defined as mean TRF ¼ P (ODi)/P (ODi/Li)
where ODi is the chemiluminescent signals and Li is the length of
TRF at position i.
2.5. Protein extraction and western blot analysis
Total proteins were extracted as previously described
(Maggisano et al., 2014). Twenty-five mg of total protein extracts
were run on a 9% or 12% SDS-PAGE gel and transferred to PVDF
membrane (VWR, Milan, Italy), blocked with TTBS/milk (TBS, 1%
Tween 20 and 5% non-fat dry milk) and incubated overnight with
affinity-purified anti-TERT (Abcam, Cambridge, United Kingdom)
and anti-GAPDH antibodies (Thermo Fisher Scientific Inc.), diluted
1:1000 and 1:50,000, respectively. The membranes were incubated
with horseradish peroxidase-conjugated anti-rabbit or anti-mouse
antibody (Transduction Laboratories, Lexington, KY, USA) in TTBS/
milk, diluted 1:5000 or 1:50,000 respectively. Western blot
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visualize the proteins.2.6. Analysis of cell proliferation and cell cycle
Cell growth of 8505C, CAL-62 and SW1736 was evaluated by
MTT assay and cell count (Celano et al., 2015). 48 h after hTERT
silencing performedwith sihTERTa, for MTTassay cells were seeded
in 96 well plates at a density of 3.5  103 and after 24, 48 and 72 h,Fig. 1. Expression of hTERT mRNA in ATCs. TERT mRNA levels in 5 FFPE thyroid tumour ti
quantification (RQ) ± SD compared with two groups of adjacent non-tumour tissues (9 FF a
Mann Whitney test. Black squares represent ATC tissues with wild type TERT; gray square
BRAFV600E and TERT C228T mutations. FF, fresh-frozen thyroid tumour tissues; FFPE, form
Fig. 2. Expression of TERT in thyroid cells. TERT mRNA (upper panel) and protein expression
1). TERTmRNA relative expression levels are reported as means ± SD of three different exper
multiple comparisons test. ****p < 0.0001. One representative of three western blot experithe solubilized product was quantified with a microplate spectro-
photometer (xMark, Biorad, Milan, Italy) at a wavelength of 540 nm
and a reference wavelength of 690 nm; for cell count assay, cells,
seeded in 12 well plates 60  103 for well, were counted in the
hematocytometric chamber. Results are expressed as percentages
over control (siCtrl), represented by cells transfected with Stealth
RNAi Negative Control Duplexes (Thermo Fisher Scientific). Trypan
blue dye exclusion assay was used to evaluate cell viability after
hTERT silencing as previously described (Bulotta et al., 2013).ssues and 5 FF thyroid tumour tissues from 10 ATC patients are expressed as relative
nd 9 FFPE). Two different analyses were carried out according to sample type by using
s represent those with TERT C228T mutation; white square represents a tissue with
alin-fixed paraffin-embedded thyroid tumour sections.
(lower panel) in ATC cells (8505C and CAL-62) and non-tumorigenic cells (Nthy-ori-3-
iments. P-values were obtained by using one way ANOVA test followed by Holm-Sidak's
ments showing TERT protein, as described in Materials and Methods, is shown.
Fig. 3. Silencing of hTERT in ATC cells. Silencing of hTERT was performed using three
different siRNAs indicated as a, b and c in CAL-62, 8505C and SW1736 cells, as
described in Materials and Methods. The picture shows one representative of three
western blot experiments for TERT protein and GAPDH which was used as loading
control.
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harvested and fixed in 70% cold ethanol at 20 C overnight. Then,
were washed and incubated with PBS containing 0.1% Triton X-100,
20 mg/ml propidium iodide and 0.05 mg/ml RNaseA for 30 min at
37 C. The stained cells were analyzed using a FAC Scan laser flow
cytometer equipped with Cell Quest software (Becton Dickinson,
San Jose, CA, USA).
2.7. Annexin V-FITC/PI staining
For apoptosis assay, Annexin V-FITC/PI staining was performed
according to the kit manufacturer's instructions (Miltenyil Biotech,
Bologna, Italy). Forty-eight hours after hTERT silencing with sih-
TERT a, 1  106 cells were plated and after 24 h, were detached by
trypsin, centrifuged and washed with 1x binding buffer. Cell pellet
was suspended in 1x binding buffer and 10 ml of Annexin V-FITC
were added. The samples were incubated for 15 min in the dark at
room temperature and then washed with 1x binding buffer. Cell
pellet was suspended in 1x binding buffer and 5 ml of PI were added
immediately prior to analysis by flow cytometry using FAC Scan
laser flow cytometer equipped with Cell Quest software (Becton
Dickinson).
2.8. Migration and invasion assays
Transwell inserts with 8 mm pore were used for cell migration
assay (Costar, Euroclone, Milan, Italy). The same inserts coated with
matrigel (Becton Dickinson) were adopted for invasion assay. Forty-
eight hours after hTERT silencing performed with sihTERT a,
60  103 cells suspended in serum-free medium containing 1% BSA
(for migration assay) or 1% FBS (for invasion detection), were plated
in the upper chamber of the inserts. As chemiotactic agent in the
bottom wells were added 600 ml of medium containing 10% FBS.
After 6 or 24 h of incubation (for detection of migration and inva-
sion, respectively), not migrated cells were removed with cotton
swabs from the upper surface of the filters which were fixed and
stained with Diff-Quick Stain (Bio Map, Monza, Italy). Finally, cells
were counted using a microscope provided with an eyepiece and
equipped with a counting grid. Results from the count of five
random fields are expressed as percentages over siCtrl.
2.9. Statistical analysis
Data of cell proliferation, migration and invasion experiments
were analyzed by one-way ANOVA followed by the Tukey-Kramer
multiple comparisons test. Intergroup differences in the expres-
sion of hTERT mRNA levels were assessed with Mann Whitney test
and Holm-Sidak's multiple comparisons test in tissue samples and
cell lines, respectively. All results are expressed as mean ± standard
deviation (SD) and were considered statistically significant p-
values lower than 0.05. All statistical analyses were performed
using GraphPad Prism version 5.0 statistical software (GraphPad
Software Inc., San Diego, CA, USA).
3. Results
3.1. Expression levels of hTERT in thyroid tumour tissues and cancer
cell lines
We first analyzed the expression levels of hTERT in 10 ATCs
characterized for the presence of BRAFV600E or hTERT promoter
mutation (Table 1) by using real-time RT-PCR. We observed that
hTERT transcript levels were significantly higher than those of a
series of normal tissues in 8 out of 10 tumours (Fig. 1). The lowest
levels of hTERT were found in two ATCs negative for the promotermutations. Higher levels of expression of both hTERT mRNA and
protein were found also in the ATC cell lines 8505C and CAL-62
compared to those of the non-tumorigenic cell line Nthy-ori-3-1
(Fig. 2).3.2. Effects on telomere length, proliferation, migration, and
invasiveness of thyroid cancer cells after siRNA-mediated silencing
of hTERT
To check the role of hTERT in ATC cells, we transfected 8505C,
CAL-62 and SW1736 cells, an additional ATC cell line hosting hTERT
promoter mutation, with three different and specific hTERT siRNAs
(sihTERT a, b, c) (Fig. 3). The strongest decrease in the levels of TERT
protein expressionwas obtainedwith sihTERT a, whichwas the only
siRNA effective on all three cell lines, in accordance with other
studies showing that a limited fraction of designed siRNAs are able
of completely silencing hTERT gene in human cancer cells (Xia et al.,
2012). Therefore, sihTERT a was used in all the following experi-
ments. When hTERT expression was downregulated, telomere
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cell lines show different telomere length (lowest in SW1736 and
highest in CAL-62) which was not modified after silencing. How-
ever, after 48 h from the start of silencing, cell viability, measured
after further 24 h by both MTT assay and cell counting, resulted
decreased ~50% over controls in all cell lines (p < 0.001 vs siCtrl)
(Fig. 4). Similar results were noted even examining the cell viability
after 48 and 72 h. Significant additional reduction of viability after
72 h, was observed only in CAL-62 (p < 0.05 vs sihTERT a 24 h)
(Fig. 4). No differences in cell viability were observed by trypan blue
assay (data not shown). In hTERT-silenced CAL-62, cytofluorimetric
analysis showed a reduction of G0/G1 phase and a block in S phase
of the cell cycle (Fig. 5), while in 8505C and SW1736 a mild block in
G0/G1 phase was observed. Moreover, annexin V-FITC/PI staining
assays (Supplementary Fig. 2) show a slight shift towards
increasing fluorescence due to presence of apoptotic cells only in
CAL-62 cells. This difference in the FACS profile probably reflects
the difference in the properties of the three cell lines, consistent
with the highly undifferentiated phenotype of ATCs, maintained
also after establishment of cell cultures. Altogether, these data
demonstrate that silencing of hTERT produces a mainly cytostatic
effect in ATC cells.
Finally, we checked the effects of silencing of hTERT on the
migration and invasive properties of the three cell lines. As shown
in Fig. 6, a significant reduction of cell migration (~60%, p < 0.001,
for 8505C and SW1736; ~50%, p < 0.01, for CAL-62 cell lines), and
invasion (~60%, p < 0.001 in 8505C and CAL-62, ~40%, p < 0.05 in
SW1736 cell lines) was observed.
4. Discussion
Treatment of ATCs represents still a major clinical challenge.
Most of patients have a very poor prognosis, mainly because are
refractory to radioiodine therapy and poorly responsive to chemo-Fig. 4. hTERT silencing reduced cellular viability of CAL-62, 8505C and SW1736 cells. Forty-e
all the cell lines, cells were plated and, after 24, 48 and 72 h, cell viability was evaluated by M
Duplexes, used as control sequence. Results are mean ± SD of three independent experimen
was performed using the Tukey-Kramer multiple comparisons test. **p < 0.01, ***p < 0.001and radiotherapy, so accounting for approximately a third of the
mortality rate caused by thyroid cancer (Smallridge et al., 2009;
Smallridge and Copland, 2010; Kojic et al., 2011; Garcia-Rostan
et al., 2015). A recent comprehensive genetic characterization of
these tumours has revealed some key genetic abnormalities which
contribute to their development (Landa et al., 2016). Among them,
mutations in hTERT promoter have been detected with high fre-
quency, confirming several previous reports (reviewed in Liu and
Xing, 2016), and strengthening the hypothesis of a role of this ge-
netic alteration in determining the aggressive behavior of these
neoplasms, especially when co-occurring with RAS/BRAF muta-
tions (Liu and Xing, 2016; Alzahrani et al., 2016; Xu and Ghossein,
2016).
In the last years, there has been an increasing interest con-
cerning the presence and frequency of hTERT mutation in thyroid
tumour tissues for their prognostic negative role, due to the
oncogenic role attributed to hTERT overexpression. Moreover,
search for hTERT promoter mutations in the materials of FNAB has
been suggested and also validated in the screening of suspicious
thyroid nodules (Alzahrani et al., 2016). However, other genomic
abnormalities have been found in ATCs. Each of them appears in
tumour tissues which do not host TERT promoter mutations (Landa
et al., 2016).
Gene silencing by using the siRNA approach is today an essential
tool to understand the roles of genes in biological functions.
Therefore, we tested the effects of hTERT gene silencing in three
human ATC cell lines which are widely used as model of aggressive
thyroid cancer. Since there are no reports on the expression of
hTERT gene in ATC tissues, we first screened a series of these tu-
mours, finding that, independent from the presence or not of the
mutations in the promoter, a higher expression of the gene was
found in most of the tumour specimens when compared to normal
thyroid tissues. In addition, expression of TERTwas observed also in
three ATC cell lines harboring (8505C and SW1736 cells) or notight hours after hTERT silencing with sihTERT a, the siRNA chosen for its effectiveness on
TT and cell count assays. siCtrl are cells transfected with Stealth RNAi Negative Control
ts performed in eigthplicate for MTT and triplicate for cell counting. Statistical analysis
vs siCtrl; p < 0.05 vs 24 h sihTERT a.
Fig. 5. Effects of hTERT silencing on cell cycle of CAL-62, 8505C and SW1736 cells. Forty-eight hours after hTERT silencing with sihTERT a, cells were plated, and after 24 h analyzed
by FACS as indicated in Materials and Methods. Figure shows the death cells and the distribution of cells in G0/G1, S and G2/M phases of the cellular cycle. The bar graphs are
representative of three independent experiments.
Fig. 6. Effect of hTERT silencing on migration and invasion of CAL-62, 8505C and
SW1736 cells. Cells, treated with sihTERT a or Stealth RNAi Negative Control Duplexes
used as control sequence (siCtrl), were prepared for migration and invasion assays as
indicated in Materials and Methods. For migration and invasion, after 6 and 24 h,
respectively, filters were stained, photographed at 10 magnification, and cells
counted. Each experiment was performed in triplicate and values are expressed as
mean ± SD from 2 independent experiments. Statistical analysis was performed using
the Tukey-Kramer multiple comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001 vs
siCtrl.
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that TERT overexpression may occur also in absence of promoter
mutations (Skvortzov et al., 2009). All lines (8505C, CAL-62 and
SW1736) were then subjected to hTERT silencing to test the role of
hTERT in cell proliferation and other parameters of aggressiveness.
Our findings demonstrate that silencing of hTERT, without
affecting the telomere length, reduces cell proliferation and causes
a decrease in invasion and migration ability of these three ATC cell
lines. It cannot be excluded the possibility that the observed
decrease in migration upon TERT silencing could partially be due to
the inhibition of cell proliferation. Similar results were alsoobtained by Teng et al., using a permanent transfection of antisense
hTERT RNA (Teng et al., 2003). The major function of telomerase is
thought to be telomere elongation; however, accumulating evi-
dences indicate that it controls expression of various genes impli-
cated in control of cell proliferation and cancer progression (Smith
et al., 2003), proposing that TERT may act as an oncogene in a
telomere-independent manner (Liu and Xing, 2016; Wyatt et al.,
2010) as seems to occur in ATCs cell lines.
These results were not surprising considering the success of this
approach in other models of human cancer. Indeed, the growth of
various cancer cells resulted inhibited by TERT silencing, even using
non-viral vectors to deliver the siRNA into the cells (Xia et al., 2012;
Shi et al., 2014; Xie et al., 2014; Li et al., 2015). Thus, considering our
present findings, targeting hTERT may be taken into consideration
even against the less differentiated and more aggressive thyroid
cancer cells.
As mentioned above, the search for hTERT promoter mutation is
now suggested and in some case adopted even in an early diag-
nostic stage of suspicious thyroid nodules (Liu and Xing, 2014). In
consideration of the potential use as therapeutic target, detection of
this biomarker, in terms of mRNA expression in FNABmaterial, may
provide useful additional information for approaching those tu-
mours unresponsive to the current treatment. While not routinely
recommended for initial postoperative risk stratification (2015 ATA
guidelines; Haugen et al., 2016), the mutational analysis of TERT
promoter has the potential to refine risk of persistent/recurrent
disease when interpreted in the context of other clinico-pathologic
risk factors. Our results show that TERT overexpression may occur
also in absence of promoter mutations and that silencing of hTERT
reduces proliferation, invasion and migration of ATC cell lines.
Therefore, we believe that also the evaluation of TERT expression
could be useful to predict risk of persistent/recurrent disease. Ge-
netic and epigenetic characterization of a neoplasm is now
considered an optimal way toward a personalized and more
effective treatment. In fact, it may allow the identification of mo-
lecular markers of a particular tumour and, if detected in an early
phase of the management of the patients, may offer novel oppor-
tunity to improve the outcome of the more aggressive tumours. In
this context, our findings demonstrate that hTERTmay represent an
optimal candidate to be targeted in the anaplastic thyroid cancer.
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